CX3CR1 and metastatic melanoma: Although it remains unclear whether T-cell CX3CR1 is a predictor of response to combination chemo-immunotherapy, Yan and colleagues demonstrated that CX3CR1+CD8+ T cells withstand treatment with chemotherapy and are increased in response to chemo-immunotherapy in patients with metastatic melanoma (22).